Zealand ac­quires a strug­gling di­a­betes med-tech in push in­to US mar­ket

Zealand Phar­ma is ex­pand­ing again.

Four months af­ter buy­ing out Cana­da’s En­cy­cle Ther­a­peu­tics and their li­brary of GI-drug­ging pep­tides, Zealand has agreed to pur­chase Va­ler­i­tas, a strug­gling med­ical tech­nol­o­gy com­pa­ny fo­cused on di­a­betes. It will cost them $23 mil­lion.

The deal pri­mar­i­ly serves as an­oth­er on­ramp for the biotech to en­ter the US mar­ket. Copen­hagen-based Zealand has pre­vi­ous­ly part­nered with large phar­ma com­pa­nies, most no­tably join­ing with Sanofi on a pair of di­a­betes drugs that in­clud­ed the biotech’s GLP-1 ana­log: Soli­qua and Lyx­u­mia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.